IL6 and psoriasis: Psoriasis is characterized as a type 17 immune-mediated disease, wherein the activation of the innate and adaptive immune system leads to the production of pro-inflammatory cytokines, including tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), interleukin-17 (IL-17), and interleukin-23 (IL-23) [32-34].